{"title":"AAV1 Vectors","description":"\u003cp\u003eReady-to-use AAV1 (AAV2\/1) vectors for efficient muscle and local CNS gene delivery — qPCR-titered and in stock.\u003c\/p\u003e","products":[{"product_id":"aav-null-aav-serotype-1-bhv21500001","title":"AAV-Null (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500001\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020164915565,"sku":"SL100802-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020164948333,"sku":"SL100802-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500001_aav-null-aav-serotype-1_SL100802.jpg?v=1770796172"},{"product_id":"aav-gfp-aav-serotype-1-bhv21500002","title":"AAV-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500002\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020164981101,"sku":"SL100803-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165013869,"sku":"SL100803-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500002_aav-gfp-aav-serotype-1_SL100803.png?v=1770796172"},{"product_id":"scaav-gfp-aav-serotype-1-self-complementary-bhv21500003","title":"scAAV-GFP (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500003\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165046637,"sku":"SL100803-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165079405,"sku":"SL100803-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500003_scaav-gfp-aav-serotype-1-self-complementary_SL100803-SC.png?v=1770796172"},{"product_id":"aav-cre-aav-serotype-1-bhv21500004","title":"AAV-Cre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500004\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165112173,"sku":"SL100804-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165144941,"sku":"SL100804-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500004_aav-cre-aav-serotype-1_SL100804.png?v=1770796172"},{"product_id":"scaav-cre-aav-serotype-1-self-complementary-bhv21500005","title":"scAAV-Cre (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500005\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165177709,"sku":"SL100804-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165210477,"sku":"SL100804-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500005_scaav-cre-aav-serotype-1-self-complementary_SL100804-SC.png?v=1770796173"},{"product_id":"aav-cre-gfp-aav-serotype-1-bhv21500006","title":"AAV-Cre-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500006\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165243245,"sku":"SL100805-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165276013,"sku":"SL100805-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500006_aav-cre-gfp-aav-serotype-1_SL100805.png?v=1770796173"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-1-bhv21500007","title":"AAV-U6-shRNA(Scramble)-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(Scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500007\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165308781,"sku":"SL100806-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165341549,"sku":"SL100806-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500007_aav-u6-shrna-scramble-gfp-aav-serotype-1_SL100806.png?v=1770796174"},{"product_id":"aav-cag-gfp-aav-serotype-1-bhv21500008","title":"AAV-CAG-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500008\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165374317,"sku":"SL100807-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165407085,"sku":"SL100807-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500008_aav-cag-gfp-aav-serotype-1_SL100807.png?v=1770796174"},{"product_id":"aav-synapsin-gfp-aav-serotype-1-bhv21500009","title":"AAV-Synapsin-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500009\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165439853,"sku":"SL100808-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165472621,"sku":"SL100808-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500009_aav-synapsin-gfp-aav-serotype-1_SL100808.png?v=1770796174"},{"product_id":"scaav-synapsin-gfp-aav-serotype-1-self-complementary-bhv21500010","title":"scAAV-Synapsin-GFP (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500010\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165505389,"sku":"SL100808-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165538157,"sku":"SL100808-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500010_scaav-synapsin-gfp-aav-serotype-1-self-complementary_SL100808-SC.png?v=1770796175"},{"product_id":"aav-mrfp-aav-serotype-1-bhv21500011","title":"AAV-mRFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mRFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500011\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emRFP is the encoded payload for this construct. A \u003cstrong\u003emRFP + RFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mRFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165570925,"sku":"SL100809-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165603693,"sku":"SL100809-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500011_aav-mrfp-aav-serotype-1_SL100809.png?v=1770796175"},{"product_id":"aav-cag-chr2-venus-aav-serotype-1-bhv21500062","title":"AAV-CAG-ChR2-Venus (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChR2-Venus\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500062\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eChR2-Venus is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChR2\u003c\/strong\u003e. A \u003cstrong\u003eVenus\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169175405,"sku":"SL100846-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169208173,"sku":"SL100846-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500062_aav-cag-chr2-venus-aav-serotype-1_SL100846.png?v=1770796192"},{"product_id":"aav-cag-chief-tdtomato-aav-serotype-1-bhv21500068","title":"AAV-CAG-ChIEF-tdTOMATO (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChIEF-tdTOMATO\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500068\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eChIEF-tdTOMATO is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChIEF\u003c\/strong\u003e. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169568621,"sku":"SL100852-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169601389,"sku":"SL100852-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500068_aav-cag-chief-tdtomato-aav-serotype-1_SL100852.png?v=1770796194"},{"product_id":"aav-lacz-aav-serotype-1-bhv21500084","title":"AAV-LacZ (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-LacZ\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500084\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLacZ is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: LacZ-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170781037,"sku":"SL100879-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020170813805,"sku":"SL100879-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500084_aav-lacz-aav-serotype-1_SL100879.png?v=1770796200"},{"product_id":"aav-cag-cre-aav-serotype-1-bhv21500086","title":"AAV-CAG-Cre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500086\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170912109,"sku":"SL100881-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020170944877,"sku":"SL100881-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500086_aav-cag-cre-aav-serotype-1_SL100881.png?v=1770796200"},{"product_id":"aav-cag-cre-gfp-aav-serotype-1-bhv21500087","title":"AAV-CAG-Cre-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500087\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170977645,"sku":"SL100882-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171010413,"sku":"SL100882-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500087_aav-cag-cre-gfp-aav-serotype-1_SL100882.png?v=1770796201"},{"product_id":"aav-u6-mirna-scramble-gfp-aav-serotype-1-bhv21500095","title":"AAV-U6-miRNA(Scramble)-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-miRNA(Scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500095\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emiRNA is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: miRNA-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171469165,"sku":"SL100890-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171501933,"sku":"SL100890-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500095_aav-u6-mirna-scramble-gfp-aav-serotype-1_SL100890.png?v=1770796204"},{"product_id":"aav-cag-dio-chief-tdtomato-aav-serotype-1-bhv21500104","title":"AAV-CAG-DIO-ChIEF-tdTOMATO (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-DIO-ChIEF-tdTOMATO\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500104\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eDIO-ChIEF-tdTOMATO is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChIEF\u003c\/strong\u003e. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003eCre-dependent (DIO\/FLEX)\u003c\/strong\u003e—the transgene is inverted and silenced by default, and flips into the active orientation only in cells expressing Cre recombinase. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003cli\u003eCre-driver dependent expression\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) Cre-driver-negative animals injected with the same DIO vector to confirm absence of leaky expression; (2) driver-positive animals without vector injection to confirm no background from the driver alone; (3) a Cre-expressing positive-control line to validate recombination efficiency; and (4) assay-matched functional or anatomical readouts to confirm payload activity only in driver-positive, vector-injected animals.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172058989,"sku":"SL100900-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172091757,"sku":"SL100900-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500104_aav-cag-dio-chief-tdtomato-aav-serotype-1_SL100900.png?v=1770796206"},{"product_id":"aav-ef1alpha-dio-chief-tdtomato-aav-serotype-1-bhv21500105","title":"AAV-EF1alpha-DIO-ChIEF-tdTOMATO (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-EF1alpha-DIO-ChIEF-tdTOMATO\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eEF1α Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500105\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eEF1α (elongation factor 1-alpha) is a strong, broadly expressed housekeeping promoter that typically maintains activity better than CMV in long-term in vivo studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eEF1alpha-DIO-ChIEF-tdTOMATO is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChIEF\u003c\/strong\u003e. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003eCre-dependent (DIO\/FLEX)\u003c\/strong\u003e—the transgene is inverted and silenced by default, and flips into the active orientation only in cells expressing Cre recombinase. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003cli\u003eCre-driver dependent expression\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) Cre-driver-negative animals injected with the same DIO vector to confirm absence of leaky expression; (2) driver-positive animals without vector injection to confirm no background from the driver alone; (3) a Cre-expressing positive-control line to validate recombination efficiency; and (4) assay-matched functional or anatomical readouts to confirm payload activity only in driver-positive, vector-injected animals.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172190061,"sku":"SL101116-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172222829,"sku":"SL101116-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500105_aav-ef1alpha-dio-chief-tdtomato-aav-serotype-1_SL101116.png?v=1770796207"},{"product_id":"aav-cag-cre-mcherry-aav-serotype-1-bhv21500106","title":"AAV-CAG-Cre-mCherry (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Cre-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500106\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-mCherry is the encoded payload for this construct. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172255597,"sku":"SL101117-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172288365,"sku":"SL101117-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500106_aav-cag-cre-mcherry-aav-serotype-1_SL101117.png?v=1770796207"},{"product_id":"aav-hsyn-dio-mcherry-aav-serotype-1-bhv21500107","title":"AAV-hSyn-DIO-mCherry (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-hSyn-DIO-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500107\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eDIO-mCherry is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eRecombinase\u003c\/strong\u003e. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003eCre-dependent (DIO\/FLEX)\u003c\/strong\u003e—the transgene is inverted and silenced by default, and flips into the active orientation only in cells expressing Cre recombinase. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003cli\u003eCre-driver dependent expression\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) Cre-driver-negative animals injected with the same DIO vector to confirm absence of leaky expression; (2) driver-positive animals without vector injection to confirm no background from the driver alone; (3) a Cre-expressing positive-control line to validate recombination efficiency; and (4) assay-matched functional or anatomical readouts to confirm payload activity only in driver-positive, vector-injected animals.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172321133,"sku":"SL101118-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172353901,"sku":"SL101118-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500107_aav-hsyn-dio-mcherry-aav-serotype-1_SL101118.png?v=1770796207"},{"product_id":"aav-hsyn-dio-gfp-aav-serotype-1-bhv21500108","title":"AAV-hSyn-DIO-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-hSyn-DIO-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500108\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eDIO-GFP is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eRecombinase\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003eCre-dependent (DIO\/FLEX)\u003c\/strong\u003e—the transgene is inverted and silenced by default, and flips into the active orientation only in cells expressing Cre recombinase. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003cli\u003eCre-driver dependent expression\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) Cre-driver-negative animals injected with the same DIO vector to confirm absence of leaky expression; (2) driver-positive animals without vector injection to confirm no background from the driver alone; (3) a Cre-expressing positive-control line to validate recombination efficiency; and (4) assay-matched functional or anatomical readouts to confirm payload activity only in driver-positive, vector-injected animals.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172386669,"sku":"SL101119-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172419437,"sku":"SL101119-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500108_aav-hsyn-dio-gfp-aav-serotype-1_SL101119.png?v=1770796208"},{"product_id":"aav-mcherry-aav-serotype-1-bhv21500112","title":"AAV-mCherry (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500112\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172648813,"sku":"SL101127-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172681581,"sku":"SL101127-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500112_aav-mcherry-aav-serotype-1_SL101127.png?v=1770796209"},{"product_id":"aav-cmv-sacas9-u6-sgrna-scramble-aav-serotype-1-bhv21500118","title":"AAV-CMV-saCas9-U6-sgRNA(Scramble) (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-saCas9-U6-sgRNA(Scramble)\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV + U6 (dual) Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500118\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThis vector uses a dual-promoter design: CMV drives protein-coding transgene expression while U6 drives shRNA expression, enabling simultaneous gene delivery and knockdown. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003esaCas9-U6-sgRNA is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003esaCas9\u003c\/strong\u003e.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: saCas9-U6-sgRNA-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020173074797,"sku":"SL101136-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020173107565,"sku":"SL101136-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500118_aav-cmv-sacas9-u6-sgrna-scramble-aav-serotype-1_SL101136.png?v=1770796211"},{"product_id":"aav-cag-icre-aav-serotype-1-bhv21500160","title":"AAV-CAG-iCre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500160\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176023917,"sku":"SL101409-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176056685,"sku":"SL101409-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500160_aav-cag-icre-aav-serotype-1_SL101409.png?v=1770796229"},{"product_id":"aav-cag-flpo-aav-serotype-1-bhv21500165","title":"AAV-CAG-FLPo (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500165\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176351597,"sku":"SL101414-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176384365,"sku":"SL101414-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500165_aav-cag-flpo-aav-serotype-1_SL101414.png?v=1770796231"},{"product_id":"aav-cmv-hascpf1-aav-serotype-1-bhv21500170","title":"AAV-CMV-hAsCpf1 (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-hAsCpf1\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500170\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003ehAsCpf1 is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: hAsCpf1-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176679277,"sku":"SL101419-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176712045,"sku":"SL101419-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500170_aav-cmv-hascpf1-aav-serotype-1_SL101419.png?v=1770796233"},{"product_id":"aav-cmv-icre-aav-serotype-1-bhv21500171","title":"AAV-CMV-iCre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500171\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176744813,"sku":"SL101426-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176777581,"sku":"SL101426-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500171_aav-cmv-icre-aav-serotype-1_SL101426.png?v=1770796233"},{"product_id":"aav-cag-luc-aav-serotype-1-bhv21500178","title":"AAV-CAG-Luc (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Luc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500178\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuciferase enables bioluminescence imaging for non-invasive in vivo tracking of transduction and gene expression. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177203565,"sku":"SL101434-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177236333,"sku":"SL101434-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500178_aav-cag-luc-aav-serotype-1_SL101434.png?v=1770796236"},{"product_id":"aav-syn-icre-aav-serotype-1-bhv21500185","title":"AAV-Syn-iCre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-iCre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500185\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177695085,"sku":"SL101441-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177727853,"sku":"SL101441-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500185_aav-syn-icre-aav-serotype-1_SL101441.png?v=1770796238"},{"product_id":"aav-syn-flpo-aav-serotype-1-bhv21500191","title":"AAV-Syn-FLPo (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500191\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178088301,"sku":"SL101447-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178121069,"sku":"SL101447-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500191_aav-syn-flpo-aav-serotype-1_SL101447.png?v=1770796240"},{"product_id":"aav-cmv-flpo-aav-serotype-1-bhv21500199","title":"AAV-CMV-FLPo (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-FLPo\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500199\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178612589,"sku":"SL101455-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178645357,"sku":"SL101455-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500199_aav-cmv-flpo-aav-serotype-1_SL101455.png?v=1770796243"},{"product_id":"aav-synapsin-cre-aav-serotype-1-bhv21500205","title":"AAV-Synapsin-Cre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500205\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179005805,"sku":"SL101461-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179038573,"sku":"SL101461-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500205_aav-synapsin-cre-aav-serotype-1_SL101461.png?v=1770796245"},{"product_id":"aav-tre-gfp-aav-serotype-1-bhv21500207","title":"AAV-TRE-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-TRE-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eTRE-Tight Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500207\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eTRE-Tight is a tetracycline-responsive element used in Tet-inducible systems; transgene expression is OFF by default and activated by doxycycline or rtTA. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eTRE-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is controlled by the \u003cstrong\u003eTet-inducible TRE system\u003c\/strong\u003e—transgene transcription is off by default and activated by administration of doxycycline or co-expression of rtTA. The promoter is designed for cell-type specificity determined by the co-expressed Cre driver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003cli\u003eInducible expression (Tet system)\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: TRE-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) no-doxycycline controls to confirm absence of leaky expression; (2) rtTA-negative animals with vector injection to confirm dependence on the transactivator; (3) dose-response characterization of doxycycline titration in your model; and (4) appropriate washout experiments to confirm reversibility of expression.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179136877,"sku":"SL101463-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179169645,"sku":"SL101463-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500207_aav-tre-gfp-aav-serotype-1_SL101463.png?v=1770796246"},{"product_id":"aav-cag-gcamp6s-aav-serotype-1-bhv21500213","title":"AAV-CAG-GCaMP6s (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GCaMP6s\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500213\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eGenetically encoded calcium indicators (GECIs) such as GCaMP permit real-time imaging of neuronal activity and calcium dynamics in vivo with single-cell resolution. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGCaMP6s is a sensitive genetically encoded calcium indicator for imaging neuronal activity at single-cell resolution. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCalcium imaging\u003c\/li\u003e\n\u003cli\u003eNeuronal activity recording\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow 2–4 weeks post-injection for stable sensor expression with AAV2\/1 in vivo.\u003c\/li\u003e\n\u003cli\u003eConfirm baseline fluorescence and responsiveness to depolarizing stimuli before experimental sessions.\u003c\/li\u003e\n\u003cli\u003eMinimize photobleaching with low-power excitation and limit imaging duration.\u003c\/li\u003e\n\u003cli\u003eUse functional controls (KCl, field stimulation) to validate sensor responsiveness in your preparation.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179530093,"sku":"SL101470-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179562861,"sku":"SL101470-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500213_aav-cag-gcamp6s-aav-serotype-1_SL101470.png?v=1770796248"},{"product_id":"aav-cag-gcamp6m-aav-serotype-1-bhv21500214","title":"AAV-CAG-GCaMP6m (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GCaMP6m\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500214\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eGenetically encoded calcium indicators (GECIs) such as GCaMP permit real-time imaging of neuronal activity and calcium dynamics in vivo with single-cell resolution. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGCaMP6m balances speed and sensitivity for calcium imaging of neural populations. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCalcium imaging\u003c\/li\u003e\n\u003cli\u003eNeuronal activity recording\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow 2–4 weeks post-injection for stable sensor expression with AAV2\/1 in vivo.\u003c\/li\u003e\n\u003cli\u003eConfirm baseline fluorescence and responsiveness to depolarizing stimuli before experimental sessions.\u003c\/li\u003e\n\u003cli\u003eMinimize photobleaching with low-power excitation and limit imaging duration.\u003c\/li\u003e\n\u003cli\u003eUse functional controls (KCl, field stimulation) to validate sensor responsiveness in your preparation.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179595629,"sku":"SL101471-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179628397,"sku":"SL101471-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500214_aav-cag-gcamp6m-aav-serotype-1_SL101471.png?v=1770796248"},{"product_id":"aav-cag-gcamp6f-aav-serotype-1-bhv21500215","title":"AAV-CAG-GCaMP6f (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GCaMP6f\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500215\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eGenetically encoded calcium indicators (GECIs) such as GCaMP permit real-time imaging of neuronal activity and calcium dynamics in vivo with single-cell resolution. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGCaMP6f is a fast calcium indicator for tracking rapid action potential-linked calcium transients. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCalcium imaging\u003c\/li\u003e\n\u003cli\u003eNeuronal activity recording\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow 2–4 weeks post-injection for stable sensor expression with AAV2\/1 in vivo.\u003c\/li\u003e\n\u003cli\u003eConfirm baseline fluorescence and responsiveness to depolarizing stimuli before experimental sessions.\u003c\/li\u003e\n\u003cli\u003eMinimize photobleaching with low-power excitation and limit imaging duration.\u003c\/li\u003e\n\u003cli\u003eUse functional controls (KCl, field stimulation) to validate sensor responsiveness in your preparation.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179661165,"sku":"SL101472-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179693933,"sku":"SL101472-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500215_aav-cag-gcamp6f-aav-serotype-1_SL101472.png?v=1770796248"},{"product_id":"aav-camkii-gcamp6m-aav-serotype-1-bhv21500216","title":"AAV-CaMKII-GCaMP6m (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CaMKII-GCaMP6m\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCaMKII Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500216\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eGenetically encoded calcium indicators (GECIs) such as GCaMP permit real-time imaging of neuronal activity and calcium dynamics in vivo with single-cell resolution. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCaMKII targets expression to excitatory neurons, particularly in the hippocampus and cortex, for region-specific manipulation of excitatory circuits. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGCaMP6m balances speed and sensitivity for calcium imaging of neural populations. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to excitatory neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCalcium imaging\u003c\/li\u003e\n\u003cli\u003eNeuronal activity recording\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow 2–4 weeks post-injection for stable sensor expression with AAV2\/1 in vivo.\u003c\/li\u003e\n\u003cli\u003eConfirm baseline fluorescence and responsiveness to depolarizing stimuli before experimental sessions.\u003c\/li\u003e\n\u003cli\u003eMinimize photobleaching with low-power excitation and limit imaging duration.\u003c\/li\u003e\n\u003cli\u003eUse functional controls (KCl, field stimulation) to validate sensor responsiveness in your preparation.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179726701,"sku":"SL101473-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179759469,"sku":"SL101473-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500216_aav-camkii-gcamp6m-aav-serotype-1_SL101473.png?v=1770796249"},{"product_id":"aav-cmv-luc-aav-serotype-1-bhv21500233","title":"AAV-CMV-Luc (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-Luc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500233\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuciferase enables bioluminescence imaging for non-invasive in vivo tracking of transduction and gene expression. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020180873581,"sku":"SL101493-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020180906349,"sku":"SL101493-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500233_aav-cmv-luc-aav-serotype-1_SL101493.png?v=1770796254"},{"product_id":"aav-luc-pest-aav-serotype-1-bhv21500235","title":"AAV-Luc-PEST (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Luc-PEST\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500235\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eLuc-PEST is the encoded payload for this construct. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-PEST-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181004653,"sku":"SL101495-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181037421,"sku":"SL101495-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500235_aav-luc-pest-aav-serotype-1_SL101495.png?v=1770796255"},{"product_id":"aav-tre-cre-aav-serotype-1-bhv21500240","title":"AAV-TRE-Cre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-TRE-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eTRE-Tight Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500240\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eTRE-Tight is a tetracycline-responsive element used in Tet-inducible systems; transgene expression is OFF by default and activated by doxycycline or rtTA. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eTRE-Cre is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is controlled by the \u003cstrong\u003eTet-inducible TRE system\u003c\/strong\u003e—transgene transcription is off by default and activated by administration of doxycycline or co-expression of rtTA. The promoter is designed for cell-type specificity determined by the co-expressed Cre driver.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003cli\u003eInducible expression (Tet system)\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) no-doxycycline controls to confirm absence of leaky expression; (2) rtTA-negative animals with vector injection to confirm dependence on the transactivator; (3) dose-response characterization of doxycycline titration in your model; and (4) appropriate washout experiments to confirm reversibility of expression.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181332333,"sku":"SL101511-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181365101,"sku":"SL101511-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500240_aav-tre-cre-aav-serotype-1_SL101511.png?v=1770796257"},{"product_id":"aav-tmck-gfp-aav-serotype-1-bhv21500244","title":"AAV-tMCK-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-tMCK-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003etMCK Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500244\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe tMCK (truncated muscle creatine kinase) promoter restricts expression to striated muscle, supporting skeletal and cardiac muscle targeting. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003etMCK-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression restricted to skeletal muscle fibers.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: tMCK-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181594477,"sku":"SL101515-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181627245,"sku":"SL101515-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500244_aav-tmck-gfp-aav-serotype-1_SL101515.png?v=1770796258"},{"product_id":"aav-tmck-mcherry-aav-serotype-1-bhv21500245","title":"AAV-tMCK-mCherry (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-tMCK-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003etMCK Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500245\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe tMCK (truncated muscle creatine kinase) promoter restricts expression to striated muscle, supporting skeletal and cardiac muscle targeting. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003etMCK-mCherry is the encoded payload for this construct. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression restricted to skeletal muscle fibers.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: tMCK-mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181660013,"sku":"SL101516-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181692781,"sku":"SL101516-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500245_aav-tmck-mcherry-aav-serotype-1_SL101516.png?v=1770796259"},{"product_id":"aav-cmv-rluc-aav-serotype-1-bhv21500255","title":"AAV-CMV-Rluc (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-Rluc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500255\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eRluc is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Rluc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182315373,"sku":"SL101533-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182348141,"sku":"SL101533-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500255_aav-cmv-rluc-aav-serotype-1_SL101533.png?v=1770796262"},{"product_id":"aav-cag-rluc-aav-serotype-1-bhv21500257","title":"AAV-CAG-Rluc (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Rluc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500257\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eRluc is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Rluc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182446445,"sku":"SL101535-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182479213,"sku":"SL101535-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500257_aav-cag-rluc-aav-serotype-1_SL101535.png?v=1770796263"},{"product_id":"aav-ef1-gfp-aav-serotype-1-bhv21500260","title":"AAV-EF1α-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-EF1α-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eEF1α Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500260\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eEF1α (elongation factor 1-alpha) is a strong, broadly expressed housekeeping promoter that typically maintains activity better than CMV in long-term in vivo studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182643053,"sku":"SL101621-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182675821,"sku":"SL101621-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500260_aav-ef1-gfp-aav-serotype-1_SL101621.png?v=1770796264"},{"product_id":"aav-ef1-mcherry-aav-serotype-1-bhv21500261","title":"AAV-EF1α-mCherry (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-EF1α-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eEF1α Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500261\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eEF1α (elongation factor 1-alpha) is a strong, broadly expressed housekeeping promoter that typically maintains activity better than CMV in long-term in vivo studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182774125,"sku":"SL101622-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182806893,"sku":"SL101622-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500261_aav-ef1-mcherry-aav-serotype-1_SL101622.png?v=1770796264"},{"product_id":"aav-cag-hgluc-aav-serotype-1-bhv21500265","title":"AAV-CAG-hGluc (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-hGluc\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500265\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003ehGluc is the encoded payload for this construct.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: hGluc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020183036269,"sku":"SL116005-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020183069037,"sku":"SL116005-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500265_aav-cag-hgluc-aav-serotype-1_SL116005.png?v=1770796266"},{"product_id":"aav-ef1-frt-gfp-aav-serotype-1-bhv21500278","title":"AAV-EF1α-FRT-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-EF1α-FRT-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eEF1α Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500278\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eEF1α (elongation factor 1-alpha) is a strong, broadly expressed housekeeping promoter that typically maintains activity better than CMV in long-term in vivo studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eFRT-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FRT-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020184019309,"sku":"SL116019-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020184052077,"sku":"SL116019-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500278_aav-ef1-frt-gfp-aav-serotype-1_SL116019.png?v=1770796270"},{"product_id":"aav-u6-shrna-scramble-mcherry-aav-serotype-1-bhv21500280","title":"AAV-U6-shRNA(Scramble)-mCherry (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(Scramble)-mCherry\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500280\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020184150381,"sku":"SL116021-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020184183149,"sku":"SL116021-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500280_aav-u6-shrna-scramble-mcherry-aav-serotype-1_SL116021.png?v=1770796271"}],"url":"https:\/\/www.ebiohippo.com\/collections\/aav1-vectors.oembed?page=2","provider":"BioHippo","version":"1.0","type":"link"}